Axa
CTMX icon

Axa’s CytomX Therapeutics CTMX Stock Holding History

Axa’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-242,100
Closed -$646K – 1130
2022
Q1 		$646K Sell
242,100
-8,800
-4% -$33.8K ﹤0.01% 1010
2021
Q4 		$1.09M Buy
250,900
+19,300
+8% +$113K ﹤0.01% 939
2021
Q3 		$1.18M Buy
+231,600
New +$1.24M ﹤0.01% 947
2021
Q1 		– Sell
-239,650
Closed -$1.57M – 1235
2020
Q4 		$1.57M Buy
239,650
+78,524
+49% +$561K ﹤0.01% 902
2020
Q3 		$1.07M Buy
161,126
+72,600
+82% +$538K ﹤0.01% 930
2020
Q2 		$737K Buy
+88,526
New +$822K ﹤0.01% 1000

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Axa's CTMX Position: Q2 2022 in Review

Axa sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 242,100 shares — an estimated $646K sold.

Axa first reported a position in CTMX in Q2 2020 and held it in 6 quarters. The position peaked at $1.57M in Q4 2020. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Axa reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Axa sold 242,100 CytomX Therapeutics shares in Q2 2022, an estimated $646K.
  • Axa first reported a position in CytomX Therapeutics in Q2 2020 and held it in 6 quarters.
  • Axa's CytomX Therapeutics position peaked at $1.57M in Q4 2020.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Axa's 13F filing for Q2 2022, filed 15 Aug 2022.